Specialty Generics Market Size To Reach $171.36 Billion By 2033

May 2026 | Report Format: Electronic (PDF)

Specialty Generics Market Growth & Trends

The global specialty generics market size is expected to reach USD 171.36 billion by 2033, registering a CAGR of 7.58% from 2026 to 2033, according to a new report by Grand View Research, Inc. The growth in the market is largely driven by increasing product approvals and the rising prevalence of complex chronic diseases, such as multiple sclerosis.

In April 2022, Dr. Reddy’s Laboratories launched a methylprednisolone sodium succinate injection in the U.S. for the treatment of patients with arthritis, blood disorders, and certain rare cancers. Furthermore, in June 2022, Elixir launched copay solutions enhancement program for the management of specialty generic medication prices. Under this program, an eligible patient receives a generic version of specialty medication at zero cost. Thus, the launch of new low-cost generic injectables and the availability of such programs is projected to fuel market growth.

Increased claim settlements and availability of specialty generic drugs increase their prescription rates due to the high safety, efficacy, and tolerability associated with them. According to the Human Resources Benefits Office University of Michigan annual report (2021), around 1,383 claims were settled for specialty generic drugs such as glatiramer acetate (Copaxone/Glatopa), teriflunomide (Aubagio), and fingolimod (Gilenya) in 2021, compared to 1,360 in 2020, with a rise of 1.7% for the treatment of patients with multiple sclerosis.

However, high costs associated with specialty generics may hamper their uptake. The lack of ability to attract patients toward drugs, marketing rights acquired by companies for off-patent drugs with no generic competition, and small target patient pool, subsequently increases the prices of products. According to the University of Michigan Prescription Drug Plan Formulary report, the average cost of specialty generic is over USD 4,500 monthly per person, compared to USD 17 to 22 for a generic prescription.

key Request a free sample copy or view report summary: Specialty Generics Market Report

Specialty Generics Market Report Highlights

Based on type, the injectables segment dominated the specialty generics industry, accounting for the largest revenue share of 62.35% in 2025. This dominance is primarily driven by the advantages of injectable formulations, including rapid onset of action, higher bioavailability, and long-acting therapeutic effects, which enhance patient compliance, particularly in oncology and chronic disease management.
Based on indication, the oncology segment is expected to grow at the fastest CAGR over the forecast period, driven by the increasing shift toward cost-effective treatment alternatives as cancer therapies become more expensive and complex.
Based on end use, the specialty pharmacy segment accounted for the largest revenue share of 77.97% in 2025, attributed to the increasing reliance on specialty pharmacies for the distribution of high-cost and complex therapies, as they offer streamlined logistics, patient support programs, and efficient reimbursement handling.
The North America specialty generics market held the largest share of 35.94% in 2025, due to the strong presence of leading generic drug manufacturers, a well-established regulatory framework, and high adoption of complex generics and biosimilars.